Compass Therapeutics, Inc. CMPX
At closeNov 4, 2026, 5:10 PM EST
After hours · Nov 4, 5:10 PM ET
- YTD
- -85.80%
- 1 year
- -79.88%
- Market cap
- 137.35M
- EPS (ttm)
- -0.39
- Shares out
- 180.09M
- Forward P/E
- -10.86
- YTD return
- -85.80%
- 1-year return
- -79.88%
- Volume
- 1.61M
- Avg volume
- 4.23M
- Open
- 0.7848
- Previous close
- 0.753
- Day's range
- 0.7541 – 0.80
- 52-week range
- 0.73 – 6.88
- Beta
- 1.30
- Analysts
- Strong Buy
- Price target
- 13.64 (+1688.8%)
2Y -0.9873 (-56.42%)
Key statistics
- Enterprise value
- 776.10M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -26.16M
- Total cash
- 208.91M
- Total debt
- 9.83M
- Return on equity
- -41.29%
- Short % of float
- 22.76%
- 50-day average
- 5.68
- 200-day average
- 4.58
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 13.64
- Target (high)
- 30.00
- Strong buy3
- Buy13
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09769.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 2026 | Guggenheim | reit | Buy | Buy |
| Jan 6, 2026 | D. Boral Capital | main | Buy | Buy |
| Jan 5, 2026 | William Blair | init | — | Outperform |
| Dec 3, 2025 | Cantor Fitzgerald | init | — | Overweight |
| Dec 3, 2025 | Citizens | init | — | Market Outperform |
| Dec 3, 2025 | Canaccord Genuity | init | — | Buy |
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- compasstherapeutics.com
News
Compass Therapeutics to Participate in Upcoming November Investor Events 
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday 
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8 
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity 
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4 
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4 
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1
Your note
Sign in to keep a note on CMPX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN JONATHAN | General Counsel | Stock Award(Grant) | Jan 1, 2026 | 171,000 |
| LERNER NEIL L | Officer | Stock Award(Grant) | Jan 1, 2026 | 382,500 |
| SCHUETZ THOMAS J. | Chief Executive Officer | Stock Award(Grant) | Jan 1, 2026 | 6,686,800 |
| SHIN BARRY | Chief Financial Officer | Stock Award(Grant) | Jan 1, 2026 | 525,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 32.21% | 16,790,809 | 87.98M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 29.20% | 15,219,994 | 79.75M | Dec 30, 2025 |
| Suvretta Capital Management, LLC | 27.21% | 14,182,379 | 74.32M | Dec 30, 2025 |
| Vivo Capital, LLC | 18.31% | 9,545,466 | 50.02M | Dec 30, 2025 |
| Blackrock Inc. | 18.01% | 9,388,624 | 49.20M | Dec 30, 2025 |
| Vanguard Group Inc | 15.44% | 8,048,374 | 42.17M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.04% | 4,190,854 | 21.96M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 6.09% | 3,174,655 | 16.64M | Feb 27, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.85% | 2,525,934 | 13.24M | Feb 27, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.18% | 1,659,129 | 8.69M | Dec 30, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.43% | 1,268,479 | 6.65M | Jan 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 1.55% | 805,577 | 4.22M | Feb 27, 2026 |